Progress in immunoconjugate cancer therapeutics.
Advances in immunoconjugate technology have revitalized the "magic bullet" concept of immunotherapeutics for the treatment of cancer. The growing availability of "human" antibodies, the increased epitope repertoire due to genomics and proteomics efforts, and advances in the means of identification and production of tumor-specific antibodies have greatly increased the potential for cancer therapeutic opportunities. Furthermore, the realization that effector molecule potency must be sufficiently high to be effective at concentrations that might realistically be delivered to the tumor site on an antibody carrier has greatly spurred the fields of medicinal chemistry and radionuclide chelate chemistry to produce such molecules.
Payne
Gillian
G
ImmunoGen Inc, 128 Sidney Street, Cambridge, MA 02139, USA. gillian.payne@immunogen.com
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000912:Antibodies, Neoplasm / Q000378:metabolism / Q000627:therapeutic use; D000951:Antigens, Neoplasm / Q000276:immunology; D003603:Cytotoxins / Q000378:metabolism / Q000627:therapeutic use; D000939:Epitopes; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D000922:Immunotoxins / Q000378:metabolism / Q000627:therapeutic use; D009369:Neoplasms / Q000000981:diagnostic imaging / Q000276:immunology / Q000628:therapy*; D016499:Radioimmunotherapy; D011877:Radionuclide Imaging
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D003603:Cytotoxins; D000939:Epitopes; D018796:Immunoconjugates; D000922:Immunotoxins